Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma

[31] Eisenhofer G., Lenders J.W., Linehan W.M., Walther M.M., Goldstein D.S., Keiser H.R., Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2, N Engl J Med, 340, pp. 1872-1879, (1999)

[32] Schlumberger M., Gicquel C., Lumbroso J., Tenenbaum F., Comoy E., Bosq J., Fonseca E., Ghillani P.P., Aubert B., Travagli J.P., Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases, J Endocrinol Invest, 15, pp. 631-642, (1992)

[33] Rao F., Keiser H.R., O'Connor D.T., Malignant pheochromocytoma: Chromaffin granule transmitters and response to treatment, Hypertension, 36, pp. 1045-1052, (2001)

[34] Anton A.H., Greer M., Sayre D.F., Williams C.M., Dihydroxyphenylalanine secretion in a malignant pheochromocytoma, Am J Med, 42, pp. 469-475, (1967)

[35] Goldstein D.S., Stull R., Eisenhofer G., Sisson J.C., Weder A., Averbuch S.D., Keiser H.R., Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma, Ann Int Med, 105, pp. 887-888, (1986)

[36] McClean D.R., Sinclair L.M., Yandle T.G., Nicholls M.G., Malignant phaeochromocytoma with high circulating DOPA, and clonidine-suppressible noradrenaline, Blood Press, 4, pp. 215-217, (1995)

[37] John H., Ziegler W.H., Hauri D., Jaeger P., Pheochromocytomas: Can malignant potential be predicted?, Urology, 53, pp. 679-683, (1999)

[38] Weyler W., Hsu Y.P., Breakefield X.O., Biochemistry and genetics of monoamine oxidase, Pharmacol Ther, 47, pp. 391-417, (1990)

[39] Lenders J.W.M., Eisenhofer G., Abeling N.G.G.M., Berger W., Murphy D.L., Konings C.H., Wagemakers L.M.B., Kopin I.J., Karoum F., Van Gennip A.H., Brunner H.G., Specific genetic deficiencies of the A and B isozymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes, J Clin Invest, 97, pp. 1010-1019, (1996)

[40] Kawamura M., Kopin I.J., Kador P.F., Sato S., Tjurmina O., Eisenhofer G., Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine, J Auton Nerv Syst, 66, pp. 145-148, (1997)

[31] Eisenhofer G., Lenders J.W., Linehan W.M., Walther M.M., Goldstein D.S., Keiser H.R., Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2, N Engl J Med, 340, pp. 1872-1879, (1999)

[32] Schlumberger M., Gicquel C., Lumbroso J., Tenenbaum F., Comoy E., Bosq J., Fonseca E., Ghillani P.P., Aubert B., Travagli J.P., Malignant pheochromocytoma: Clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases, J Endocrinol Invest, 15, pp. 631-642, (1992)

[33] Rao F., Keiser H.R., O'Connor D.T., Malignant pheochromocytoma: Chromaffin granule transmitters and response to treatment, Hypertension, 36, pp. 1045-1052, (2001)

[34] Anton A.H., Greer M., Sayre D.F., Williams C.M., Dihydroxyphenylalanine secretion in a malignant pheochromocytoma, Am J Med, 42, pp. 469-475, (1967)

[35] Goldstein D.S., Stull R., Eisenhofer G., Sisson J.C., Weder A., Averbuch S.D., Keiser H.R., Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma, Ann Int Med, 105, pp. 887-888, (1986)

[36] McClean D.R., Sinclair L.M., Yandle T.G., Nicholls M.G., Malignant phaeochromocytoma with high circulating DOPA, and clonidine-suppressible noradrenaline, Blood Press, 4, pp. 215-217, (1995)

[37] John H., Ziegler W.H., Hauri D., Jaeger P., Pheochromocytomas: Can malignant potential be predicted?, Urology, 53, pp. 679-683, (1999)

[38] Weyler W., Hsu Y.P., Breakefield X.O., Biochemistry and genetics of monoamine oxidase, Pharmacol Ther, 47, pp. 391-417, (1990)

[39] Lenders J.W.M., Eisenhofer G., Abeling N.G.G.M., Berger W., Murphy D.L., Konings C.H., Wagemakers L.M.B., Kopin I.J., Karoum F., Van Gennip A.H., Brunner H.G., Specific genetic deficiencies of the A and B isozymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes, J Clin Invest, 97, pp. 1010-1019, (1996)

[40] Kawamura M., Kopin I.J., Kador P.F., Sato S., Tjurmina O., Eisenhofer G., Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine, J Auton Nerv Syst, 66, pp. 145-148, (1997)